Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-02-01
2005-02-01
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
Reexamination Certificate
active
06849661
ABSTRACT:
The present invention is directed to methods of treating, preventing, and/or managing abnormal increases in gastrointestinal motility, and intestinal conditions that cause the same. Such conditions include, but are not limited to, irritable bowel syndrome (IBS), infectious diseases of the small and large intestines, and symptoms of any of the foregoing. In particular, the present invention discloses methods of using enriched (R)-verapamil, as well as compositions and formulations containing the same.
REFERENCES:
patent: 5889060 (1999-03-01), Harding
patent: 5892093 (1999-04-01), Bannister et al.
patent: 5910601 (1999-06-01), McCague et al.
patent: 5932246 (1999-08-01), Harding et al.
patent: 5955500 (1999-09-01), Longstreth et al.
patent: 6190691 (2001-02-01), Mak
patent: 6267980 (2001-07-01), Gilbert et al.
patent: WO 9744025 (1997-11-01), None
patent: WO 9805321 (1998-02-01), None
Medline an 1999063874, Marvola et al, Eur. J. Pharmaceutical Sci. 1999 Feb 7(3) 259-67, abstract.*
Echizen et al. “The Effect of Dextro-, Levo-, and Racemic Verapamil on Atrioventricular Conduction in Humans,”American Heart Journal, 109: 210-217, 1985.
Echizen et al., “Effects of D,L-Verapamil on Atrioventricular Conduction in Relation to Its Stereoselective First-Pass Metabolism,”Clinical Pharmacology&Therapeutics, 38: 71-76, 1985.
Echizen et al., “Electrophysiologic Effects of Dextro- and Levo- Verapamil on Sinus Node and AV Node Function in Humans,”Journal of Cardiovascular Pharmacology, 12(5): 543-546, 1988.
Kroemer et al., “Predictability of the in Vivo Metabolism of Verapamil from in Vitro Data: Contribution of Individual Metabolic Pathways and Stereoselective Aspects,”The Journal of Pharmacology and Experimental Therapeutics, 260(3): 1052-1057, 1992.
Miwa et al., “Patients with Constipation-Predominant Irritable Bowel Syndrome (IBS) May Have Elevated Serotonin Concentrations in Colonic Mucosa as Compared with Diarrhea-Predominant Patients and Subjects with Normal Bowel Habits,”Digestion, 63: 188-194, 2001.
Vogelgesang et al., “Stereoselective First-Pass Metabolism of Highly Cleared Drugs: Studies of the Bioavailability of L- and D-Verapamil Examined with a Stable Isotope Techique,”British Journal of Clinical Pharmacology, 18: 733-740, 1984.
Co-pending U.S. Application No. 10/256,261, filed Sep. 27, 2002.
Ahlman et al., “Verapamil and Diarrhoea in the Carcinoid Syndrome- Clinical and Experimental Observations on Serotonin Release,”Br. J. Cancer, 54:251-256, 1986.
Beubler et al., “Involvement of 5-Hydroxytrptamine, Prostaglandin E2, and Cyclic Adenosine Monophosphate in Cholera Toxin-Induced Fluid Secretion in the Small Intestine of the Rat In Vivo,”Gastroenterology, 96: 368-76, 1989.
Borsari et al., “L'effet thérapeutique de L'anticalcique Vérapamil dans la Diarrhée Chronique,”Schweiz. Med. Wschr., 121:1238-1242, 1991 (English-language abstract included).
Byrne, “Verapamil in the Treatment of Irritable Bowel Syndrome,”J. Clin. Psy., 48:9, 1987.
Cox et al., “Effect of Antisecretory Drugs on Experimentally Induced Weanling Diarrhoea in Piglets,”Commun., 13(12): 159-70, 1989.
de Ponti et al., “Inhibitory Effects of Calcium Channel Blockers on Intestinal Motility in the Dog,”Eur. J. Pharmacol., 168(2): 133-44, 1989.
Donowitz et al., “Ca2+Channel Blockers Stimulate Ileal and Colonic Water Absorption,”Gastroenterology, 89(4):858-66, 1985.
Fabia et al., “Effect of Putative Phospholipase A2 Inhibitors on Acetic Acid-Induced Acute Colitis in the Rat,”Br. J. Surg., 80: 1199-1204, 1993.
Fedorak et al., “Verapamil Alters Eicosanoid Synthesis and Accelerates Healing During Experimental Colitis in Rats,”Gastroenterology, 102: 1229-1235, 1992.
Floch, “Use of Verapamil in the Treatment of Diarrhea due to Microscopic Colitis,”J. Clin. Gastroenterol., 32(4): 283, 2001.
Gertner et al,, Verapamil Inhibits In-Vitro Leucotriene B4 Release by Rectal Mucosa in Active Ulcerative Colitis,Aliment. Pharmacol. Ther., 6: 163-68, 1992.
Goyal et al., Studies on the Mechanism ofEscherichia coliHeat-Stble Enterotoxin-Induced Diarrhoea in Mice,Biochemica et Biophysica Acta, 925: 341-346, 1987.
Gullikson et al., “Inhibition of Intestinal Secretion in the Dog: A New Approach for the Management of Diarrheal States,”J. Pharmacol. Exp. Ther., 219: 591-97, 1981.
Hedner et al., “Calcium Channel Blockers: Spectrum of Side Effects and Drug Interactions,”Acta Pharmacol. Toxicol., 58(Suppl 2):119-30, 1986.
Homaidan et al., “Electrolyte Transport in Piglets Infected With Transmissable Gastroenteritis Virus,”Gastroenterology, 101: 895-901, 1991.
Kanwar et al., “Calcium and Protein Kinase C Play an Important Role inCampylobacter Jejuni-induced changes in Na+and CI Transport in Rat Ileum In Vitro,”Biochemica et Biophysica Acta, 1270: 179-192, 1995.
Khurana, et al., “Studies on the Mechanism of Salmonella Typhimurium Enterotoxin-Induced Diarrhoes,” Biochim.Biophys. Acta, 1097(3):171-76, 1991.
Köksoy et al., “The Prophylactic Effects of Superoxide Dismutase, Catalase, Desferrioxamine, Verapamil, and Disulfiram in Experimental Colitis,”J. R. Coll. Surg. Edinb., 42: 27-30, 1997.
Krevsky et al., “Effect of Verapamil on Human Intestinal Transit,”Dig. Dis. Sci., 37(6):919-924, 1992.
Lee et al., “Ca2+Channel Blockade by Verapamil Inhibits GMCs and Diarrhea During Small Intestinal Inflammation,”American J. Phys., 36: G785-94, 1997.
McCleod, “Verapamil Effective in Irritable Bowel Syndrome?”Med. J. Aust., 2(3):119 (letter), 1983
Piascik, “Stereoselective and Nonstereoselective Inhibition Exhibited by the Enantiomers of Verapamil,”Can. J. Physiol. Pharmacol., 68(3):439-446, 1990.
Satoh et al., “Coronary Vasodilator and Cardiac Effects of Optical Isomers of Verapamil in the dog,”J. Cardio. Pharm., 2:309-318, 1980.
Scheidler et al., “Use of Verapamil for the Symptomatic Treatment of Microscopic Colitis,”J. Clin. Gastroenterol., 32: 351-352, 2001.
Simmonds et al., “Antioxidant Effects of Aminosalicylates and Potential New Drugs for Inflammatory Bowel Disease: Assessment in Cell-Free Systems and Inflamed Human Colorectal Biopsies,”Aliment. Pharmacol. Ther., 13: 363-372, 1999.
Subissi et al., “Effects of Spasmolytics on K+-Induced Contraction of Rat Intestine In Vivo,”European J. Pharmacol., 96: 295-301, 1983.
Tabibian, “Successful Treatment of Refractory Post-Vagotomy Syndrome with Verapamil,”Am. J. Gastroenterol., 85: 328-29, 1990.
Thollander et al., “Dihydropyridine Calcium Channel Antagonists Disrupt Migrating Myoelectric Complexes and Counteract Intestinal Disorders Associated With Morphine Withdrawal Diarrhea,”Scand. J. Gastroenterol., 28: 137-144, 1993.
Thulin et al., “Side Effects of Calcium Channel Blockers,”Scand. J. Prim. Health Care Suppl., 1:81-84, 1990.
Camilleri et al., “Review Article: Irritable Bowel Syndrome,”Aliment. Pharmaco. Ther., 11(1): 3-15, 1997.
Cherukuri et al., “Verapamil in Resistant Diarrhoea Predominant Subtype of Irritable Bowel Syndrome (IBS),”Gastroenterology, 106(4) Suppl.: A478, 1994.
Freeman et al., “Verapamil Therapy for Persistent Antral Spasms in a Child,”Southern Medical Journal, 89(5): 529-530, 1996.
Longstreth, “Verapamil a Chiral Challenge to the Pharmacoklnetic and Pharmacodynamic Assessment of Bioavailability and Bioequivalence,”Drug Stereochemistry, 18: 315-336, 1993.
Devane John
Dinan Ted G.
Keeling P.W. Napoleon
Kelly John
AGI Therapeutics Ltd.
Cook Rebecca
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
LandOfFree
Treatment of abnormal increases in gastrointestinal motility... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of abnormal increases in gastrointestinal motility..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of abnormal increases in gastrointestinal motility... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3446989